2026.Nov.13

Corporate

OBI Pharma Signs Collaboration and License Agreement with Novartis

OBI Pharma, Inc. (4174.TWO) (“OBI”) announced that it has entered into a Collaboration and License agreement with Novartis Pharma AG (“Novartis”) to develop next generation Antibody-Drug-Conjugates (ADCs) with novel payloads, using OBI’s suite of platform technologies.

HOMEWhat’s NewNewsOBI Pharma Signs Collaboration and License Agreement with Novartis

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2026.Oct.07

Following Presidential Office Recognition, OBI Pharma Showcases the Strength of Its Obrion® ADC Platform and Accelerates Global Licensing to Capture Expanding Market Opportunities